Silicone rubber vaginal contraceptive devices of four different formulations, which release predetermined, controlled doses of three progestogens at four distinct levels, were designed and fabricated, and tested in 90-day clinical trials. Data obtained with 70 of the devices indicated that in vivo release rates (μg/day ± S.D.) for the formulations were: progesterone, 1400 ± 30; norethindrone (two levels), 49.4 ± 2.4, 196 ± 21; d-norgestrel, 21.6 ± 1.4. Clinical studies with these devices indicate that the women usually ovulate (with the exception of the high-dose norethindrone-releasing devices) while sperm penetration of the cervix was inhibited by all four formulations, most consistently by the norgestrel-releasing devices. © 1979.